Population pharmacokinetics of arbekacin in burn patients
The aim of this study was to estimate the pharmacokinetics (PK) of arbekacin in burn patients using a population–PK approach. Therapeutic drug monitoring data consisting of 126 plasma concentrations (including 17 values that were below the quantitation limit) from 47 burn patients were retrospective...
Saved in:
| Published in | European journal of clinical pharmacology Vol. 64; no. 6; pp. 599 - 603 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Berlin/Heidelberg
Springer-Verlag
01.06.2008
Springer Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The aim of this study was to estimate the pharmacokinetics (PK) of arbekacin in burn patients using a population–PK approach. Therapeutic drug monitoring data consisting of 126 plasma concentrations (including 17 values that were below the quantitation limit) from 47 burn patients were retrospectively analyzed using a mixed effect method (
NONMEM
, ver. 6.0). Covariates, such as burn index, age, sex, among others, were tested on the basic one-compartment model. In the basic model, positive correlations of body weight (WT) and creatinine clearance (CLcr) on total clearance (CL) and volume of distributions (V) were assumed. In the final model, V increased with burn index (BI). The final model was:
;
. Between-subject variability in terms of CL and V were 35 and 39%, respectively. The CL of our burn patients was significantly greater than that reported in unburned patients, and V increased proportionally with increasing BI. |
|---|---|
| AbstractList | The aim of this study was to estimate the pharmacokinetics (PK) of arbekacin in burn patients using a population-PK approach. Therapeutic drug monitoring data consisting of 126 plasma concentrations (including 17 values that were below the quantitation limit) from 47 burn patients were retrospectively analyzed using a mixed effect method (NONMEM, ver. 6.0). Covariates, such as burn index, age, sex, among others, were tested on the basic one-compartment model. In the basic model, positive correlations of body weight (WT) and creatinine clearance (CLcr) on total clearance (CL) and volume of distributions (V) were assumed. In the final model, V increased with burn index (BI). The final model was: CL(L/h) = 3.18x WT/ 70 + 4.49x CLcr/120; V(L) = 27.5x WT/70 + 0.28x (BI-23.5). Between-subject variability in terms of CL and V were 35 and 39%, respectively. The CL of our burn patients was significantly greater than that reported in unburned patients, and V increased proportionally with increasing BI. The aim of this study was to estimate the pharmacokinetics (PK) of arbekacin in burn patients using a population-PK approach. Therapeutic drug monitoring data consisting of 126 plasma concentrations (including 17 values that were below the quantitation limit) from 47 burn patients were retrospectively analyzed using a mixed effect method (NONMEM, ver. 6.0). Covariates, such as burn index, age, sex, among others, were tested on the basic one-compartment model. In the basic model, positive correlations of body weight (WT) and creatinine clearance (CLcr) on total clearance (CL) and volume of distributions (V) were assumed. In the final model, V increased with burn index (BI). The final model was: CL(L/h) = 3.18x WT/ 70 + 4.49x CLcr/120; V(L) = 27.5x WT/70 + 0.28x (BI-23.5). Between-subject variability in terms of CL and V were 35 and 39%, respectively. The CL of our burn patients was significantly greater than that reported in unburned patients, and V increased proportionally with increasing BI.The aim of this study was to estimate the pharmacokinetics (PK) of arbekacin in burn patients using a population-PK approach. Therapeutic drug monitoring data consisting of 126 plasma concentrations (including 17 values that were below the quantitation limit) from 47 burn patients were retrospectively analyzed using a mixed effect method (NONMEM, ver. 6.0). Covariates, such as burn index, age, sex, among others, were tested on the basic one-compartment model. In the basic model, positive correlations of body weight (WT) and creatinine clearance (CLcr) on total clearance (CL) and volume of distributions (V) were assumed. In the final model, V increased with burn index (BI). The final model was: CL(L/h) = 3.18x WT/ 70 + 4.49x CLcr/120; V(L) = 27.5x WT/70 + 0.28x (BI-23.5). Between-subject variability in terms of CL and V were 35 and 39%, respectively. The CL of our burn patients was significantly greater than that reported in unburned patients, and V increased proportionally with increasing BI. The aim of this study was to estimate the pharmacokinetics (PK) of arbekacin in burn patients using a population-PK approach. Therapeutic drug monitoring data consisting of 126 plasma concentrations (including 17 values that were below the quantitation limit) from 47 burn patients were retrospectively analyzed using a mixed effect method (NONMEM, ver. 6.0). Covariates, such as burn index, age, sex, among others, were tested on the basic one-compartment model. In the basic model, positive correlations of body weight (WT) and creatinine clearance (CLcr) on total clearance (CL) and volume of distributions (V) were assumed. In the final model, V increased with burn index (BI). The final model was: $$ CL{\left( {L \mathord{\left/ {\vphantom {L h}} \right. \kern-\nulldelimiterspace} h} \right)} = 3.18x{WT} \mathord{\left/ {\vphantom {{WT} {70}}} \right. \kern-\nulldelimiterspace} {70} + 4.49x{CLcr} \mathord{\left/ {\vphantom {{CLcr} {120}}} \right. \kern-\nulldelimiterspace} {120} $$;$$ V{\left( L \right)} = 27.5x{WT} \mathord{\left/ {\vphantom {{WT} {70}}} \right. \kern-\nulldelimiterspace} {70} + 0.28x{\left( {BI - 23.5} \right)} $$. Between-subject variability in terms of CL and V were 35 and 39%, respectively. The CL of our burn patients was significantly greater than that reported in unburned patients, and V increased proportionally with increasing BI. [PUBLICATION ABSTRACT] The aim of this study was to estimate the pharmacokinetics (PK) of arbekacin in burn patients using a population–PK approach. Therapeutic drug monitoring data consisting of 126 plasma concentrations (including 17 values that were below the quantitation limit) from 47 burn patients were retrospectively analyzed using a mixed effect method (NONMEM, ver. 6.0). Covariates, such as burn index, age, sex, among others, were tested on the basic one-compartment model. In the basic model, positive correlations of body weight (WT) and creatinine clearance (CLcr) on total clearance (CL) and volume of distributions (V) were assumed. In the final model, V increased with burn index (BI). The final model was: ;. Between-subject variability in terms of CL and V were 35 and 39%, respectively. The CL of our burn patients was significantly greater than that reported in unburned patients, and V increased proportionally with increasing BI. The aim of this study was to estimate the pharmacokinetics (PK) of arbekacin in burn patients using a population–PK approach. Therapeutic drug monitoring data consisting of 126 plasma concentrations (including 17 values that were below the quantitation limit) from 47 burn patients were retrospectively analyzed using a mixed effect method ( NONMEM , ver. 6.0). Covariates, such as burn index, age, sex, among others, were tested on the basic one-compartment model. In the basic model, positive correlations of body weight (WT) and creatinine clearance (CLcr) on total clearance (CL) and volume of distributions (V) were assumed. In the final model, V increased with burn index (BI). The final model was: ; . Between-subject variability in terms of CL and V were 35 and 39%, respectively. The CL of our burn patients was significantly greater than that reported in unburned patients, and V increased proportionally with increasing BI. |
| Author | Yim, Dong-Seok Kim, Jong Hyun Lah, Hyon-oh |
| Author_xml | – sequence: 1 givenname: Jong Hyun surname: Kim fullname: Kim, Jong Hyun organization: Department of Surgery, Hangang Sacred Heart Hospital, College of Medicine, Hallym University – sequence: 2 givenname: Hyon-oh surname: Lah fullname: Lah, Hyon-oh organization: Department of Pharmacology, College of Medicine, The Catholic University of Korea – sequence: 3 givenname: Dong-Seok surname: Yim fullname: Yim, Dong-Seok email: yimds@catholic.ac.kr organization: Department of Pharmacology, College of Medicine, The Catholic University of Korea, Department of Pharmacology, The Catholic University of Korea |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20395250$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18320181$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU9P3DAQxS0EgoXyAbhUqyJ6C52xHSc5Voj-kZDaAz1bE69NDVl7aycHvn2d7hYkJJDGmsvvjd_MO2b7IQbL2BnCJQI0nzIA520FUJ5soMI9tkApeIUgcZ8tAARWqmvgiB3nfA-AdQfikB1hKzhgiwvW_YybaaDRx7Dc_Ka0JhMffLCjN3kZ3ZJSbx_I-LAs1U-pUAW2Yczv2IGjIdvTXT9hv75c3159q25-fP1-9fmmMrITY-UEKtsB7xwKx6WpTWtaXDlaEQrkNTUN2Z56gL4hZxQ1fUewUmS4ISWlOGEft3M3Kf6ZbB712mdjh4GCjVPWZT9e1wIKeP4CvI_FcPGmuVJSqVriPO7DqxRK2RZTokDvd9DUr-1Kb5JfU3rU_-9WgIsdQNnQ4BIF4_MTx0F0Na9nT82WMynmnKzTxo__rj0m8oNG0HOSepukLknqOUk9_4AvlE8m3tDwrSYXNtzZ9Lzb66K_ZdmtWg |
| CitedBy_id | crossref_primary_10_1016_j_burns_2009_09_001 crossref_primary_10_1016_j_burns_2015_01_001 crossref_primary_10_1097_FTD_0000000000000678 crossref_primary_10_1128_AAC_00505_18 |
| Cites_doi | 10.1097/00005373-197610000-00014 10.1093/jac/44.3.319 10.1016/S0305-4179(98)00058-8 10.1016/S0002-9610(96)00346-7 10.1016/j.biopha.2003.12.012 10.1093/jac/35.6.865 10.1128/AAC.00420-05 10.1093/clinids/14.2.458 10.1093/infdis/124.Supplement_1.S185 10.1128/AAC.34.5.792 10.1097/00005373-197610000-00013 10.1136/bmj.1.5906.477 |
| ContentType | Journal Article |
| Copyright | Springer-Verlag 2008 2008 INIST-CNRS Springer-Verlag 2008. |
| Copyright_xml | – notice: Springer-Verlag 2008 – notice: 2008 INIST-CNRS – notice: Springer-Verlag 2008. |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7RV 7TK 7U9 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1007/s00228-008-0470-1 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest One Academic Middle East (New) ProQuest One Academic Middle East (New) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1432-1041 |
| EndPage | 603 |
| ExternalDocumentID | 1471241281 18320181 20395250 10_1007_s00228_008_0470_1 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -4W -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 04C 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 28- 29G 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3SX 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67N 67Z 6NX 6PF 78A 7RV 7X7 88E 8AO 8FI 8FJ 8FW 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYOK AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFO ACGFS ACHSB ACHVE ACHXU ACIHN ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACREN ACZOJ ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADOJX ADRFC ADTPH ADURQ ADYFF ADYOE ADYPR ADZKW AEAQA AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFFNX AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFYQB AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BMSDO BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS ECT EIHBH EIOEI EJD EMB EMOBN EN4 EPAXT ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- MK0 N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TSG TSK TSV TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK6 WK8 WOW Y6R YLTOR Z45 Z7U Z7V Z7W Z81 Z82 Z83 Z87 Z8O Z8P Z8Q Z8U Z8V Z8W Z91 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT ABRTQ IQODW PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7TK 7U9 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c493t-f316e9029f13f24c5c8c81dfada13125a77aebab00b7afc6a7b9a0d6ac2ca6443 |
| IEDL.DBID | U2A |
| ISSN | 0031-6970 |
| IngestDate | Mon Jul 21 11:23:17 EDT 2025 Fri Jul 25 05:51:52 EDT 2025 Fri Jul 25 06:57:13 EDT 2025 Mon Jul 21 05:42:43 EDT 2025 Mon Jul 21 09:15:37 EDT 2025 Tue Jul 01 01:41:05 EDT 2025 Thu Apr 24 23:11:56 EDT 2025 Fri Feb 21 02:46:49 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Burn Population pharmacokinetics Arbekacin NONMEM Human Antibiotic Aminoglycoside Protein synthesis inhibitor Antibacterial agent |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c493t-f316e9029f13f24c5c8c81dfada13125a77aebab00b7afc6a7b9a0d6ac2ca6443 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 18320181 |
| PQID | 214481313 |
| PQPubID | 47171 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_69725530 proquest_journals_2664665414 proquest_journals_214481313 pubmed_primary_18320181 pascalfrancis_primary_20395250 crossref_citationtrail_10_1007_s00228_008_0470_1 crossref_primary_10_1007_s00228_008_0470_1 springer_journals_10_1007_s00228_008_0470_1 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2008-06-01 |
| PublicationDateYYYYMMDD | 2008-06-01 |
| PublicationDate_xml | – month: 06 year: 2008 text: 2008-06-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Berlin – name: Heidelberg – name: Germany |
| PublicationTitle | European journal of clinical pharmacology |
| PublicationTitleAbbrev | Eur J Clin Pharmacol |
| PublicationTitleAlternate | Eur J Clin Pharmacol |
| PublicationYear | 2008 |
| Publisher | Springer-Verlag Springer Springer Nature B.V |
| Publisher_xml | – name: Springer-Verlag – name: Springer – name: Springer Nature B.V |
| References | Cameron, Muller, Faoagali (CR7) 1998; 24 Boucher, Kuhl, Hickerson (CR6) 1992; 14 Weinbren (CR12) 1999; 44 Yamamura, Kawada, Takehira, Nishizawa, Katayama, Hirano (CR13) 2004; 58 Rybak, Albrecht, Berman, Warbasse, Svensson (CR8) 1990; 34 Fry (CR5) 1996; 172 Zaske, Bootman, Solem, Strate (CR4) 1982; 91 Tanigawara, Sato, Morita, Kaku, Aikawa, Shimizu (CR11) 2006; 50 Jackson, Riff (CR1) 1971; 124 Suppl Zaske, Sawchuk, Gerding, Strate (CR9) 1976; 16 Glew, Moellering, Burke (CR2) 1976; 16 Noone, Parsons, Pattison, Slack, Garfield-Davies, Hughes (CR3) 1974; 1 Hamilton-Miller, Shah (CR10) 1995; 35 MJ Weinbren (470_CR12) 1999; 44 DE Zaske (470_CR9) 1976; 16 DE Fry (470_CR5) 1996; 172 Y Tanigawara (470_CR11) 2006; 50 GG Jackson (470_CR1) 1971; 124 Suppl MJ Rybak (470_CR8) 1990; 34 DE Zaske (470_CR4) 1982; 91 RH Glew (470_CR2) 1976; 16 P Noone (470_CR3) 1974; 1 BA Boucher (470_CR6) 1992; 14 DR Cameron (470_CR7) 1998; 24 JM Hamilton-Miller (470_CR10) 1995; 35 S Yamamura (470_CR13) 2004; 58 4206128 - Br Med J. 1974 Mar 16;1(5906):477-81 1554831 - Clin Infect Dis. 1992 Feb;14(2):458-63 994263 - J Trauma. 1976 Oct;16(10):824-8 994262 - J Trauma. 1976 Oct;16(10):819-23 9003686 - Am J Surg. 1996 Dec;172(6A):20S-25S 2360818 - Antimicrob Agents Chemother. 1990 May;34(5):792-5 9725691 - Burns. 1998 Aug;24(5):475-7 5001620 - J Infect Dis. 1971 Dec;124 Suppl:S185-91 7058491 - Surgery. 1982 Feb;91(2):142-9 15183849 - Biomed Pharmacother. 2004 May;58(4):239-44 10511398 - J Antimicrob Chemother. 1999 Sep;44(3):319-27 7559197 - J Antimicrob Chemother. 1995 Jun;35(6):865-8 17065621 - Antimicrob Agents Chemother. 2006 Nov;50(11):3754-62 |
| References_xml | – volume: 34 start-page: 792 year: 1990 end-page: 795 ident: CR8 article-title: Vancomycin pharmacokinetics in burn patients and intravenous drug abusers publication-title: Antimicrob Agents Chemother – volume: 16 start-page: 824 year: 1976 end-page: 828 ident: CR9 article-title: Increased dosage requirements of gentamicin in burn patients publication-title: J Trauma doi: 10.1097/00005373-197610000-00014 – volume: 91 start-page: 142 year: 1982 end-page: 149 ident: CR4 article-title: Increased burn patient survival with individualized dosages of gentamicin publication-title: Surgery – volume: 1 start-page: 477 year: 1974 end-page: 481 ident: CR3 article-title: Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis publication-title: Br Med J – volume: 44 start-page: 319 year: 1999 end-page: 327 ident: CR12 article-title: Pharmacokinetics of antibiotics in burn patients publication-title: J Antimicrob Chemother doi: 10.1093/jac/44.3.319 – volume: 24 start-page: 475 year: 1998 end-page: 477 ident: CR7 article-title: Burn wound excision and massive blood transfusion did not affect perioperative vancomycin levels publication-title: Burns doi: 10.1016/S0305-4179(98)00058-8 – volume: 172 start-page: 20S year: 1996 end-page: 25S ident: CR5 article-title: The importance of antibiotic pharmacokinetics in critical illness publication-title: Am J Surg doi: 10.1016/S0002-9610(96)00346-7 – volume: 14 start-page: 458 year: 1992 end-page: 463 ident: CR6 article-title: Pharmacokinetics of systemically administered antibiotics in patients with thermal injury publication-title: Clin Infect Dis – volume: 58 start-page: 239 year: 2004 end-page: 244 ident: CR13 article-title: Artificial neural network modeling to predict the plasma concentration of aminoglycosides in burn patients publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2003.12.012 – volume: 35 start-page: 865 year: 1995 end-page: 868 ident: CR10 article-title: Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant publication-title: J Antimicrob Chemother doi: 10.1093/jac/35.6.865 – volume: 50 start-page: 3754 year: 2006 end-page: 3762 ident: CR11 article-title: Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00420-05 – volume: 16 start-page: 819 year: 1976 end-page: 823 ident: CR2 article-title: Gentamicin dosage in children with extensive burns publication-title: J Trauma – volume: 124 Suppl start-page: S185 year: 1971 end-page: S191 ident: CR1 article-title: Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin publication-title: J Infect Dis – volume: 14 start-page: 458 year: 1992 ident: 470_CR6 publication-title: Clin Infect Dis doi: 10.1093/clinids/14.2.458 – volume: 58 start-page: 239 year: 2004 ident: 470_CR13 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2003.12.012 – volume: 124 Suppl start-page: S185 year: 1971 ident: 470_CR1 publication-title: J Infect Dis doi: 10.1093/infdis/124.Supplement_1.S185 – volume: 44 start-page: 319 year: 1999 ident: 470_CR12 publication-title: J Antimicrob Chemother doi: 10.1093/jac/44.3.319 – volume: 35 start-page: 865 year: 1995 ident: 470_CR10 publication-title: J Antimicrob Chemother doi: 10.1093/jac/35.6.865 – volume: 50 start-page: 3754 year: 2006 ident: 470_CR11 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00420-05 – volume: 34 start-page: 792 year: 1990 ident: 470_CR8 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.34.5.792 – volume: 24 start-page: 475 year: 1998 ident: 470_CR7 publication-title: Burns doi: 10.1016/S0305-4179(98)00058-8 – volume: 16 start-page: 824 year: 1976 ident: 470_CR9 publication-title: J Trauma doi: 10.1097/00005373-197610000-00014 – volume: 91 start-page: 142 year: 1982 ident: 470_CR4 publication-title: Surgery – volume: 16 start-page: 819 year: 1976 ident: 470_CR2 publication-title: J Trauma doi: 10.1097/00005373-197610000-00013 – volume: 172 start-page: 20S year: 1996 ident: 470_CR5 publication-title: Am J Surg doi: 10.1016/S0002-9610(96)00346-7 – volume: 1 start-page: 477 year: 1974 ident: 470_CR3 publication-title: Br Med J doi: 10.1136/bmj.1.5906.477 – reference: 10511398 - J Antimicrob Chemother. 1999 Sep;44(3):319-27 – reference: 4206128 - Br Med J. 1974 Mar 16;1(5906):477-81 – reference: 9725691 - Burns. 1998 Aug;24(5):475-7 – reference: 994262 - J Trauma. 1976 Oct;16(10):819-23 – reference: 9003686 - Am J Surg. 1996 Dec;172(6A):20S-25S – reference: 2360818 - Antimicrob Agents Chemother. 1990 May;34(5):792-5 – reference: 7058491 - Surgery. 1982 Feb;91(2):142-9 – reference: 5001620 - J Infect Dis. 1971 Dec;124 Suppl:S185-91 – reference: 15183849 - Biomed Pharmacother. 2004 May;58(4):239-44 – reference: 1554831 - Clin Infect Dis. 1992 Feb;14(2):458-63 – reference: 17065621 - Antimicrob Agents Chemother. 2006 Nov;50(11):3754-62 – reference: 994263 - J Trauma. 1976 Oct;16(10):824-8 – reference: 7559197 - J Antimicrob Chemother. 1995 Jun;35(6):865-8 |
| SSID | ssj0015903 |
| Score | 1.8562886 |
| Snippet | The aim of this study was to estimate the pharmacokinetics (PK) of arbekacin in burn patients using a population–PK approach. Therapeutic drug monitoring data... The aim of this study was to estimate the pharmacokinetics (PK) of arbekacin in burn patients using a population-PK approach. Therapeutic drug monitoring data... |
| SourceID | proquest pubmed pascalfrancis crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 599 |
| SubjectTerms | Adolescent Adult Aged Aged, 80 and over Anti-Infective Agents - pharmacokinetics Arbekacin Biological and medical sciences Biomedical and Life Sciences Biomedicine Body weight Burn patients Burn treatment Burns Burns - metabolism Creatinine Dibekacin - analogs & derivatives Dibekacin - pharmacokinetics Drug therapy Female Humans Male Medical sciences Metabolic Clearance Rate Middle Aged Models, Biological Pharmacokinetics Pharmacokinetics and Disposition Pharmacology Pharmacology. Drug treatments Pharmacology/Toxicology Quantitation Retrospective Studies Therapeutic drug monitoring Traumas. Diseases due to physical agents |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB6V7aUSqugLwlLqQ8WhxcJxHCc5oaoqQpVa7QGkvUVjx5YQKLsly4F_zzjxZoUKSLnZjpx5eMYe5_sAvpKdSPRoeaW85IoCIMdGpTzTjSuF8U71YM9__urzS_V7ns_j3ZwuXqtcr4n9Qt0sbDgjPwnQXmWapdnp8h8PpFGhuBoZNLbgdUAuC0ZdzMf9FgVqETF3U66rYixqih5DVAZo5lD7V4Xg6aOwtL3EjiTkB2qLp3LP_-qmfTg624G3MY9kPwbFv4NXrn0PR7MBiPr-mF1s_qvqjtkRm20gqu8_QDUbebvYMrZcU74ZerOFZ3hr3DXaq5bRQ2KnXgP-avcRLs9-Xfw855FEgVuS_Ir7LNWuErLyaealsrktLeWoHhskacociwKdQfI-U6C3GgtToWg0WmmRkqXsE0zaRev2gHna_jhTWopnFPedMCbPVG4aUbqG_LhJQKxlWNuIMB6ILm7qERu5F3vdM1-S2Os0gW_jkOUAr_FS58NHihlHSJFVoTybwHStqTq6YlePhpPAwROtWivdc6En8GVsJhcLdRNs3eKuq8l2ZGBXSmB30P5mqrQeBsSzBL6vzWHz6me_Y__FaU7hzXAnJZz0HMBkdXvnPlPiszKHvXk_AFMe_Xs priority: 102 providerName: ProQuest |
| Title | Population pharmacokinetics of arbekacin in burn patients |
| URI | https://link.springer.com/article/10.1007/s00228-008-0470-1 https://www.ncbi.nlm.nih.gov/pubmed/18320181 https://www.proquest.com/docview/214481313 https://www.proquest.com/docview/2664665414 https://www.proquest.com/docview/69725530 |
| Volume | 64 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swED_68VIoY-u6zWuX6mH0oatAtmXZfkxGstKxEEoD6ZORZAlKhxPq9KH__U7yRyjNBgODHnQS1p1Od9JJvwP4ivMkklZqmnMbUY4GkMqShzQWpcmYsoZ7sOdfU3E159eLZNG-46672-5dSNKv1P1jNw_VQn24nqeM4pZnP8Gtu7vHNY-GfeggyVmLtBtSkad9KHNbFy-M0eFK1sgX2yS02OZxvoqWeiM0eQtvWu-RDBtxv4MdUx3B-ayBn36-JLeb11T1JTknsw0w9fN7yGd9ti6yamse0Mt01GRpiXxU5kHq-4rgh8xGqgZ1tT6G-WR8-_2KtqkTqEZ-r6mNQ2FyFuU2jG3EdaIzjZ6plaUMUTqJTFNplESdU6m0WshU5ZKVQupIS3SR4g-wVy0r8wmIxU2PUZlGK4bW3jClkpgnqmSZKVF7ywBYx8NCt7jiLr3F76JHRPZsL3y-S2R7EQZw0TdZNaAa_yIevBBM3yJice6CsgGcdJIqWgWsC4cEl-FQ4wBOt9QKwYXPgB7AWV-NiuWiJbIyy6e6wLkTuZxKAXxspL_5VVwFHc5ZAN-66bDp-q_j-Pxf1Cdw0NxMcec9p7C3fnwyX9D9WasB7KaLdAD7w8loNHXlj7ufYyxH4-nsZuCV4Q_jZQAG |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9wwEB5ROLRSVZWWtikUfAAOFAvHcZzkUFUVLVrKQ3tYpL2ltmNLFSi7kEXV_qj-x47zWiEoN6Tc_JAzM_aMPfb3AWyjnXDllKGZcJwKdIBUFSKkkSxsyrSzogZ7PjuXgwvxcxyPl-Bv9xbGX6vs1sR6oS4mxp-RH3horzSMwujr9Jp60iifXO0YNBqrOLHzP7hjq74cf0f17nB-9GN0OKAtqQA1OJIZdVEobcZ45sLIcWFikxqM2ZwqFPbOY5UkymqF1qgT5YxUic4UK6Qy3CgMHiLs9xmsoN9lfq-XjPv9HQYGrMX4DanMkj6JymrMUu6hoP1dA5EwGt5xgy-nqkKNuIZK46FY916etnZ_R6_hVRu3km-Noa3Cki3fwO6wAb6e75PR4h1XtU92yXABiT1_C9mw5wkj07bkEuNbX5tMHFE32l4q87sk-KGasVaD91qtwcWTyPcdLJeT0n4A4nC7ZXVq0H9inGGZ1nEkYl2w1Ba4bhQBsE6GuWkRzT2xxlXeYzHXYs9rpk0Uex4GsNc3mTZwHo9V3ryjmL4FZ1Hm08EBrHeaytupX-W9oQaw8UCplELW3OsBbPXFOKV9nkaVdnJb5Wg73LM5BfC-0f5iqLj-eoS1AD535rDo-r__8fHRYW7B88Ho7DQ_PT4_WYcXzX0Yf8q0Acuzm1v7CYOumd6sTZ3Ar6eeW_8A_BY8LQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrYSQEOJNaGl9gB6gVh3HcZIDQkC7aimsItRKvaW2Y0uoVXbbbIX2p_HvGOe1qii9VcrNduJ4xuOxZ_x9AG9RT7hyytBMOE4FLoBUlSKkkSxtyrSzogF7_jGR-8fi20l8sgJ_-rswPq2yt4mNoS6nxp-R73horzSMwmjHdVkR-e740-yCegIpH2jt2TRaDTm0i9-4e6s_HuyiqN9xPt47-rpPO4IBarBXc-qiUNqM8cyFkePCxCY16L85VSr8Eo9VkiirFWqmTpQzUiU6U6yUynCj0JGI8L33YDXxm6IRrH7Zm-Q_hxBGnLEO8TekMkuGkCprEEy5B4b2mQciYTS8tig-nKka5eNaYo2bPN9_orbNYjh-DI86L5Z8btXuCazY6ils5S0M9mKbHC1vddXbZIvkS4DsxTPI8oE1jMy6kjP0dn1tMnVEXWp7psyviuCDQsdaLfpr_RyO72SEX8Comlb2FRCHmy-rU4OrKXodlmkdRyLWJUttiVakDID1Y1iYDt_c02ycFwMyczPsRcO7icNehAG8H5rMWnCP2ypvXBPM0IKzKPPB4QDWekkVnSGoi0FtA1i_oVRKIRsm9gA2h2Kc4D5qoyo7vaoL1B3uuZ0CeNlKf9lVtMYeby2AD706LF_93_94fWs3N-E-zqvi-8HkcA0etMkx_shpHUbzyyv7Bj2wud7odJ3A6V1Pr787a0HI |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Population+pharmacokinetics+of+arbekacin+in+burn+patients&rft.jtitle=European+journal+of+clinical+pharmacology&rft.au=JONG+HYUN+KIM&rft.au=LAH%2C+Hyon-Oh&rft.au=YIM%2C+Dong-Seok&rft.date=2008-06-01&rft.pub=Springer&rft.issn=0031-6970&rft.volume=64&rft.issue=6&rft.spage=599&rft.epage=603&rft_id=info:doi/10.1007%2Fs00228-008-0470-1&rft.externalDBID=n%2Fa&rft.externalDocID=20395250 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-6970&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-6970&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-6970&client=summon |